Rosenson, Robert S.
Brewer, H. Bryan Jr
Ansell, Benjamin J.
Barter, Philip
Chapman, M. John
Heinecke, Jay W.
Kontush, Anatol
Tall, Alan R.
Webb, Nancy R.
Article History
First Online: 1 September 2015
Competing interests
: R.S.R. has served as a member of advisory boards for Amgen, AstraZeneca, Eli Lilly, Genzyme, GlaxoSmithKline, Novartis, Regeneron, and Sanofi; received honoraria from Kowa, travel support from LipoScience, and royalties from UpToDate, Inc.; and participates in clinical trials sponsored by Amgen, AstraZeneca, and Sanofi. H.B.B. has served as a member of advisory boards for Amgen, AstraZeneca, CSL, Eli Lilly, Merck, Pifzer, and Roche; received honoraria from Amgen, AstraZeneca, CSL, Eli Lilly, Merck, Pfizer, and Roche; received travel support from Amgen, AstraZeneca, Eli Lilly, Merck, and Roche; participates in clinical trials sponsored by Eli Lilly and Roche; is a patent holder for HDL Therapeutics; and receives royalties from AstraZeneca. B.J.A. is a member of an advisory board for Amgen; receives honoraria from Kowa; and is a shareholder in Amgen and Bruin Pharma. P.B. is a member of advisory boards for AstraZeneca, CSL, Merck, Novartis, Pfizer, and Roche; has received honoraria form Abbott, AstraZeneca, Merck, Novartis, Pfizer, and Roche; and participates in clinical trials sponsored by AstraZeneca, Merck, Pfizer, and Roche. J.C. receives research funding from CSL, Kowa, and Pfizer; is a member of advisory boards for Amgen, CSL, Danone, Merck, and Sanofi-Regeneron; has received honoraria from Amgen, Danone, Merck, Sanofi-Regeneron, and Unilever; participates in a clinical trial sponsored by AstraZeneca; and is a patent holder on the use of negatively charged phospholipids to optimize the biological function of recombinant HDL. J.W.H. is a member of advisory boards for Amgen, Bristol Myers Squibb, GlaxoSmithKline, Insilicos, and Merck; and is a patent holder for the use of oxidation markers to predict the risk of cardiovascular disease. A.K. participates in a clinical trial sponsored by CSL; and is a patent holder for the use of negatively charged phospholipids to optimize the biological function of recombinant HDL. A.R.T. is a member of advisory boards for Amgen, Arisaph, CSL, Eli Lilly, and Pfizer. N.R.W. declares no competing interests.